We are discovering and developing novel antiviral compounds to treat viral infections including Coronavirus and Influenza Virus infections by leveraging our proprietary drug discovery platform.

We are leveraging our core competencies and decade of experience in antiviral therapeutics to combat the global COVID-19 health crisis. Our COVID-19 program consists of work performed by our contract research organization partners around the world and in our own laboratory. Given the growing global need for a treatment, we are advancing preclinical development of antiviral therapeutics targeting SARS-CoV-2 as quickly and efficiently as possible, while advancing the discovery and development of antiviral compounds for other high-value indications.